Health-related quality of life outcomes in patients with rheumatoid arthritis and ankylosing spondylitis after tapering biologic treatment

Ming Han Chen, Mei Hsuan Lee, Hsien Tzung Liao, Wei Sheng Chen, Chien Chih Lai, Chang Youh Tsai

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Treatment with biological disease-modifying anti-rheumatic drugs (bDMARDs) for rheumatoid arthritis (RA) and ankylosing spondylitis (AS) is popular. The aim of this study was to investigate changes in the quality of life (QoL) in patients after receiving, tapering, or stopping bDMARD treatment. Three hundred and thirty patients with RA and 120 patients with AS were enrolled. Data on the patients receiving bDMARDs were obtained by self-completed questionnaires including the short-form 36 (SF-36) and Global Quality of Life (GQL) scale. A relapse was defined as the QoL becoming worse than that before bDMARD treatment. Significant improvement in all domains of the SF-36 and GQL was noted in the patients after receiving bDMARDs. Improvement in SF-36 was significantly greater in RA patients with a shorter disease duration (< 6 years) and milder patient-assessed disease activity and in AS patients with a shorter disease duration and younger age. There were significant decreases in all domains of the SF-36 and GQL in both groups after reducing/discontinuing bDMARD treatment. The patients in both groups with a shorter period of bDMARD treatment (≤ 3 years) had significantly worse SF-36 scores compared to those with a longer period of bDMARD treatment (> 3 years). The relapse rate after reducing/discontinuing treatment was over 90.0% in the RA patients and over 50.0% in the AS patients within 12 months. bDMARDs significantly improved the QoL of the patients with RA and AS. However, interrupting or stopping the treatment protocol worsened the QoL and led to relapses, especially in the patients who used bDMARDs for a shorter period.

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalClinical Rheumatology
DOIs
Publication statusAccepted/In press - Jan 6 2018

Fingerprint

Ankylosing Spondylitis
Antirheumatic Agents
Rheumatoid Arthritis
Quality of Life
Therapeutics
Recurrence
Clinical Protocols

Keywords

  • AS
  • Biologic
  • Dose reduction
  • QoL
  • RA

ASJC Scopus subject areas

  • Rheumatology

Cite this

Health-related quality of life outcomes in patients with rheumatoid arthritis and ankylosing spondylitis after tapering biologic treatment. / Chen, Ming Han; Lee, Mei Hsuan; Liao, Hsien Tzung; Chen, Wei Sheng; Lai, Chien Chih; Tsai, Chang Youh.

In: Clinical Rheumatology, 06.01.2018, p. 1-10.

Research output: Contribution to journalArticle

Chen, Ming Han ; Lee, Mei Hsuan ; Liao, Hsien Tzung ; Chen, Wei Sheng ; Lai, Chien Chih ; Tsai, Chang Youh. / Health-related quality of life outcomes in patients with rheumatoid arthritis and ankylosing spondylitis after tapering biologic treatment. In: Clinical Rheumatology. 2018 ; pp. 1-10.
@article{d456a1315c214cbeb170b2ab45821bc1,
title = "Health-related quality of life outcomes in patients with rheumatoid arthritis and ankylosing spondylitis after tapering biologic treatment",
abstract = "Treatment with biological disease-modifying anti-rheumatic drugs (bDMARDs) for rheumatoid arthritis (RA) and ankylosing spondylitis (AS) is popular. The aim of this study was to investigate changes in the quality of life (QoL) in patients after receiving, tapering, or stopping bDMARD treatment. Three hundred and thirty patients with RA and 120 patients with AS were enrolled. Data on the patients receiving bDMARDs were obtained by self-completed questionnaires including the short-form 36 (SF-36) and Global Quality of Life (GQL) scale. A relapse was defined as the QoL becoming worse than that before bDMARD treatment. Significant improvement in all domains of the SF-36 and GQL was noted in the patients after receiving bDMARDs. Improvement in SF-36 was significantly greater in RA patients with a shorter disease duration (< 6 years) and milder patient-assessed disease activity and in AS patients with a shorter disease duration and younger age. There were significant decreases in all domains of the SF-36 and GQL in both groups after reducing/discontinuing bDMARD treatment. The patients in both groups with a shorter period of bDMARD treatment (≤ 3 years) had significantly worse SF-36 scores compared to those with a longer period of bDMARD treatment (> 3 years). The relapse rate after reducing/discontinuing treatment was over 90.0{\%} in the RA patients and over 50.0{\%} in the AS patients within 12 months. bDMARDs significantly improved the QoL of the patients with RA and AS. However, interrupting or stopping the treatment protocol worsened the QoL and led to relapses, especially in the patients who used bDMARDs for a shorter period.",
keywords = "AS, Biologic, Dose reduction, QoL, RA",
author = "Chen, {Ming Han} and Lee, {Mei Hsuan} and Liao, {Hsien Tzung} and Chen, {Wei Sheng} and Lai, {Chien Chih} and Tsai, {Chang Youh}",
year = "2018",
month = "1",
day = "6",
doi = "10.1007/s10067-017-3965-2",
language = "English",
pages = "1--10",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer London",

}

TY - JOUR

T1 - Health-related quality of life outcomes in patients with rheumatoid arthritis and ankylosing spondylitis after tapering biologic treatment

AU - Chen, Ming Han

AU - Lee, Mei Hsuan

AU - Liao, Hsien Tzung

AU - Chen, Wei Sheng

AU - Lai, Chien Chih

AU - Tsai, Chang Youh

PY - 2018/1/6

Y1 - 2018/1/6

N2 - Treatment with biological disease-modifying anti-rheumatic drugs (bDMARDs) for rheumatoid arthritis (RA) and ankylosing spondylitis (AS) is popular. The aim of this study was to investigate changes in the quality of life (QoL) in patients after receiving, tapering, or stopping bDMARD treatment. Three hundred and thirty patients with RA and 120 patients with AS were enrolled. Data on the patients receiving bDMARDs were obtained by self-completed questionnaires including the short-form 36 (SF-36) and Global Quality of Life (GQL) scale. A relapse was defined as the QoL becoming worse than that before bDMARD treatment. Significant improvement in all domains of the SF-36 and GQL was noted in the patients after receiving bDMARDs. Improvement in SF-36 was significantly greater in RA patients with a shorter disease duration (< 6 years) and milder patient-assessed disease activity and in AS patients with a shorter disease duration and younger age. There were significant decreases in all domains of the SF-36 and GQL in both groups after reducing/discontinuing bDMARD treatment. The patients in both groups with a shorter period of bDMARD treatment (≤ 3 years) had significantly worse SF-36 scores compared to those with a longer period of bDMARD treatment (> 3 years). The relapse rate after reducing/discontinuing treatment was over 90.0% in the RA patients and over 50.0% in the AS patients within 12 months. bDMARDs significantly improved the QoL of the patients with RA and AS. However, interrupting or stopping the treatment protocol worsened the QoL and led to relapses, especially in the patients who used bDMARDs for a shorter period.

AB - Treatment with biological disease-modifying anti-rheumatic drugs (bDMARDs) for rheumatoid arthritis (RA) and ankylosing spondylitis (AS) is popular. The aim of this study was to investigate changes in the quality of life (QoL) in patients after receiving, tapering, or stopping bDMARD treatment. Three hundred and thirty patients with RA and 120 patients with AS were enrolled. Data on the patients receiving bDMARDs were obtained by self-completed questionnaires including the short-form 36 (SF-36) and Global Quality of Life (GQL) scale. A relapse was defined as the QoL becoming worse than that before bDMARD treatment. Significant improvement in all domains of the SF-36 and GQL was noted in the patients after receiving bDMARDs. Improvement in SF-36 was significantly greater in RA patients with a shorter disease duration (< 6 years) and milder patient-assessed disease activity and in AS patients with a shorter disease duration and younger age. There were significant decreases in all domains of the SF-36 and GQL in both groups after reducing/discontinuing bDMARD treatment. The patients in both groups with a shorter period of bDMARD treatment (≤ 3 years) had significantly worse SF-36 scores compared to those with a longer period of bDMARD treatment (> 3 years). The relapse rate after reducing/discontinuing treatment was over 90.0% in the RA patients and over 50.0% in the AS patients within 12 months. bDMARDs significantly improved the QoL of the patients with RA and AS. However, interrupting or stopping the treatment protocol worsened the QoL and led to relapses, especially in the patients who used bDMARDs for a shorter period.

KW - AS

KW - Biologic

KW - Dose reduction

KW - QoL

KW - RA

UR - http://www.scopus.com/inward/record.url?scp=85040085463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040085463&partnerID=8YFLogxK

U2 - 10.1007/s10067-017-3965-2

DO - 10.1007/s10067-017-3965-2

M3 - Article

AN - SCOPUS:85040085463

SP - 1

EP - 10

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

ER -